Clinical trials: Drug Eluting Stents
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Stable Angina, Unstable Angina
International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions
The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.
- Conditions
- Stable Angina, Unstable Angina, Documented Silent Ischemia
- Trial name
- NEXT (NCT01373502)
- Testing
- DES Limus Carbostent, Taxus Liberté Stent
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 323 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease, Coronary Stenosis
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)
This study compares angiographic and clinical outcomes in patients with long coronary lesions treated with sirolimus-eluting stent (Ultimaster stent) or everolimus-eluting stent (Xience Alpine stent).
- Trial name
- LONG-DES VII (NCT03484234)
- Testing
- Ultimaster stent, Xience alpine stent
- Where
- 2 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Seung-Jung Park
In-stent Restenosis
Diffuse Type In-Stent Restenosis After Drug-Eluting Stent
To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.
- Trial name
- DES-ISR (NCT00485030)
- Testing
- Cypher, Xience-V
- Where
- 15 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seung-Jung Park
Coronary Disease, Coronary Artery Disease
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT00180466
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 697 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.
- Trial name
- ISAR-SAFE (NCT00661206)
- Testing
- Clopidogrel
- Where
- 40 sites in United States, Albania and 11 more
- Volunteers
- 4,005 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Bypass Grafting
Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents
Hypothesis: Sealing moderate SVG lesions with paclitaxel-eluting stents reduces cardiac events (death, myocardial infarction, target vessel revascularization) over the duration of follow-up.
- Trial name
- VELETI II (NCT01223443)
- Testing
- Paclitaxel eluting stent
- Where
- Canada
- Volunteers
- 125 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Angina, Unstable, Diabetes Mellitus
Efficacy Study of Nicorandil on Neointima
The investigators aim to investigate the effect of oral nicorandil on neointima after coronary drug-eluting stent implantation in patients with diabetic mellitus.
- Trial name
- NCT02328521
- Testing
- Nicorandil
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhang Ying Qian
Coronary Artery Disease
Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study
Vascular effects evaluation after non-polimeric and polimeric paclitaxel stent implantation.In particular the investigators will use Taxus )as a polimeric stent)and Axxion (as a non-polimeirc)stent system.
- Trial name
- LISAII (NCT01375855)
- Testing
- Percutaneous transluminal Coronary Angioplasty
- Where
- Spain
- Volunteers
- 320 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Coronary Artery Disease, Restenoses, Coronary
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
The hypothesis of the study is, that there is a significant interaction in treatment effect between the OCT pattern of neointima (heterogeneous or homogeneous) and the type of percutaneous coronary intervention (drug-eluting…
- Trial name
- ISAR-DESIRE5 (NCT05544864)
- Testing
- Drug eluting stent (DES), Drug coated ballloon (DCB)
- Where
- 5 sites in Germany, Spain
- Volunteers
- 376 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
V-Flex Plus PTX Drug Eluting Coronary Stent
The study is intended to collect data to evaluate effectiveness and safety of drug eluting stent devices in a dose ranging assessment.
- Trial name
- ELUTES III (NCT00225693)
- Testing
- drug eluting coronary stent
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease
A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions
The clinical investigation is an international, prospective, multi-center, double-blind, randomized safety and efficacy trial. The purpose of this study is to evaluate the safety and effectiveness of the TAXUS(TM)Stent System…
- Trial name
- TAXUS VI (NCT00297804)
- Testing
- TAXUS Express Paclitaxel-Eluting Coronary Stent System, Control stent
- Where
- Germany
- Volunteers
- 448 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
de Novo Lesions in Native Coronary Arteries
First in Man Trial - BIOSOLVE-I
First in Man Trial with the drug eluting absorbable metal scaffold. To assess safety
- Trial name
- BIOSOLVE-I (NCT01168830)
- Testing
- AMS-3.0
- Where
- 6 sites in Belgium, Germany and 2 more
- Volunteers
- 46 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
Comparison of DCB and DES for Severe Calcification of de Novo Lesion in Elderly CHD
The goal of this clinical trial was to compare the effectiveness of drug balloons versus drug-coated stents in calcified lesions in elderly coronary artery disease.
- Trial name
- NCT05750771
- Testing
- DES, DCB
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Coronary Artery Disease
Pressure-wire Guided PTCA: Drug Eluting Stent Versus Drug Eluting Balloon (WinDEB Study)
The aim of the study is to show the safety and efficacy of the SeQuent® Please (Drug Eluting Balloon or DEB) vs. commonly used Drug Eluting Stents in the treatment of small vessel disease and side branches by pressure wire guided…
- Trial name
- NCT01399463
- Testing
- Angioplasty performed via Paclitaxel Eluting Balloon catheter, Angioplasty via DES
- Sponsor
- Medical University of Vienna
Coronary Artery Disease
A Trial of DCB vs DES in the Treatment of de Novo Large Diameter Coronary Atherosclerotic Stenosis(LARGE ONE)
For the treatment of primary large-diameter coronary atherosclerosis through percutaneous coronary intervention (PCI), the use of a drug balloon (DCB) is not inferior to the placement of a drug-eluting stent (Firehawk™ family).
- Trial name
- LARGE-ONE (NCT05961787)
- Testing
- SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Peripheral Vascular Disease, Critical Limb Ischemia
Drug Eluting Stents In The Critically Ischemic Lower Leg
The Destiny trial compares the use of bare metal stent systems with drug eluting stent systems in the treatment of infrapopliteal lesions in patients with Critical Limb Ischemia.
- Trial name
- DESTINY (NCT00510393)
- Testing
- XIENCE V everolimus eluting coronary stent system, MULTILINK VISION coronary stent system
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 140 people
- Sponsor
- Flanders Medical Research Program
Coronary Artery Disease
Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).
- Trial name
- LARGER-DCB (NCT06954714)
- Testing
- Drug-eluting stent implantation, Drug-coated balloon angioplasty
- Where
- 8 sites in South Korea
- Volunteers
- 256 people
- Sponsor
- Chonnam National University Hospital
Coronary Artery Disease
The Direct III Post Market Study
The primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated…
- Trial name
- Direct III (NCT02693158)
- Where
- 8 sites in Netherlands
- Volunteers
- 440 people
- Sponsor
- Svelte Medical Systems, Inc.